Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Insider awards and holdings reported for Colgate-Palmolive (CL). On 09/11/2025 the reporting person received a restricted stock unit (RSU) award of 3,450 shares that vests in three equal annual installments, and a stock option to buy 23,888 shares with an exercise price of $84.06. The option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the grant and expires on 09/11/2033.
Following the reported transactions the reporting person beneficially owned 16,062 shares directly and 8,004 shares indirectly through the issuer's 401(k) plan trustee. The report was signed by an attorney-in-fact on 09/12/2025.
Colgate-Palmolive officer Hazlin John reported equity awards granted on 09/11/2025. The filing shows a grant of 4,045 restricted stock units (RSUs) and a stock option award covering 28,007 shares with an exercise price of $84.06. Following the RSU grant, Ms. John directly beneficially owns 18,455 shares and indirectly holds 5,382 shares through the issuer's 401(k) plan trustee.
The stock option vests in equal annual installments over three years beginning on 09/11/2026 and expires on 09/11/2033. The RSUs vest in three equal one-year installments starting on the grant date.
Malcolm Gregory, Executive Vice President and Controller of Colgate-Palmolive Company (CL), reported equity awards granted on 09/11/2025. He received 1,119 restricted stock units (RSUs) that vest in three equal annual installments beginning one year after grant and 7,743 stock options with an exercise price of $84.06. The options vest in equal annual installments over three years beginning on the first anniversary of the grant and expire on 09/11/2033. Following these transactions, Mr. Gregory directly beneficially owns 12,146 shares and indirectly owns 8,445 shares through the issuer's 401(k) plan trustee.
Grant Shane, COO, Americas at Colgate-Palmolive Company, reported equity awards on 09/11/2025. The filing shows a grant of 3,569 restricted stock units (RSUs) that vest in equal one-third installments on each of the first three anniversaries of the grant. The report also records a stock option award for 24,712 shares with an exercise price of $84.06; the option vests in equal annual installments over three years beginning on the first anniversary of the grant and expires on 09/11/2033. After these transactions, the reporting person beneficially owns 94,119 common shares and holds 24,712 underlying shares from the option award.
Jennifer Daniels, Chief Legal Officer and Secretary of Colgate-Palmolive Company (CL), reported equity awards granted on 09/11/2025. The filing shows a non-derivative acquisition of 4,592 common stock units (restricted stock units) at $0.00, leaving 77,980 shares directly beneficially owned after the transaction, plus 1,813 indirectly owned through the issuer's 401(k) plan trustee. The filing also reports a stock option award with an $84.06 exercise price for 31,796 options, exercisable in equal annual installments over three years beginning on the first anniversary of the 09/11/2025 grant and expiring 09/11/2033. The RSUs vest in three equal annual installments from the grant date. The form is signed by an attorney-in-fact on 09/12/2025.
Colgate-Palmolive (NYSE: CL) filed an 8-K dated 1 Aug 2025 reporting two material items.
- Item 2.02 – Earnings release: The Q2-25 earnings press release was furnished as Exhibit 99; the filing itself contains no revenue, EPS or margin data and is not deemed “filed” for Exchange Act liability purposes.
- Item 2.05 – Three-year Productivity Program: Approved 31 Jul 2025, the initiative is intended to support the company’s 2030 strategy by streamlining the organisational structure and optimising the global supply chain. Management expects cumulative pre-tax charges of $200-$300 million, classified in the Corporate segment, with substantially all costs recognised by 31 Dec 2028.
The company cautions that forward-looking statements about timing and amount of charges may differ materially from current projections. No cost-savings targets, head-count impacts or earnings guidance were disclosed.